Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation

Phylinda L S Chan, John Nutt, Nicholas H G Holford

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Purpose. To externally validate the model predictions of a DATATOP cohort analysis through application of clinical trial simulation with the study design of the ELLDOPA trial. Methods. The stochastic pharmacokinetic-pharmacodynamic and disease progress model was developed from the large DATATOP cohort of patients followed for 8 years. ELLDOPA was designed to detect a difference between placebo and levodopa treated arms in the total Unified Parkinson's Disease Rating Scale (UPDRS) taken at baseline and following 2 weeks levodopa washout after 40 weeks of treatment. The total UPDRS response was simulated with different assumptions on levodopa effect (symptomatic with/without disease modifying capability) and washout speed of symptomatic effect. Results. The observed results of ELLDOPA were similar to the model predictions assuming levodopa slows disease progression and has a slow washout of symptomatic effect. Conclusions. This simulation work confirmed the conclusion of the DATATOP analysis finding that levodopa slows disease progression. The simulation results also showed that a dose-related increased rate of progression in Parkinson's disease, obscured by symptomatic benefit, is very unlikely. Finally, the simulation results also shown that 2 weeks washout period was not adequate to completely eliminate the symptomatic benefits of levodopa.

Original languageEnglish (US)
Pages (from-to)791-802
Number of pages12
JournalPharmaceutical Research
Volume24
Issue number4
DOIs
StatePublished - Apr 2007

Fingerprint

Levodopa
Parkinson Disease
Clinical Trials
Disease Progression
Secondary Parkinson Disease
Pharmacodynamics
Pharmacokinetics
Cohort Studies
Placebos

Keywords

  • Clinical trial simulation
  • DATATOP
  • Disease progress model
  • ELLDOPA
  • Parkinson's disease
  • Protective treatment

ASJC Scopus subject areas

  • Chemistry(all)
  • Pharmaceutical Science
  • Pharmacology

Cite this

Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation. / Chan, Phylinda L S; Nutt, John; Holford, Nicholas H G.

In: Pharmaceutical Research, Vol. 24, No. 4, 04.2007, p. 791-802.

Research output: Contribution to journalArticle

@article{57ee9a8c60d340aebc9ea2ff04638a57,
title = "Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation",
abstract = "Purpose. To externally validate the model predictions of a DATATOP cohort analysis through application of clinical trial simulation with the study design of the ELLDOPA trial. Methods. The stochastic pharmacokinetic-pharmacodynamic and disease progress model was developed from the large DATATOP cohort of patients followed for 8 years. ELLDOPA was designed to detect a difference between placebo and levodopa treated arms in the total Unified Parkinson's Disease Rating Scale (UPDRS) taken at baseline and following 2 weeks levodopa washout after 40 weeks of treatment. The total UPDRS response was simulated with different assumptions on levodopa effect (symptomatic with/without disease modifying capability) and washout speed of symptomatic effect. Results. The observed results of ELLDOPA were similar to the model predictions assuming levodopa slows disease progression and has a slow washout of symptomatic effect. Conclusions. This simulation work confirmed the conclusion of the DATATOP analysis finding that levodopa slows disease progression. The simulation results also showed that a dose-related increased rate of progression in Parkinson's disease, obscured by symptomatic benefit, is very unlikely. Finally, the simulation results also shown that 2 weeks washout period was not adequate to completely eliminate the symptomatic benefits of levodopa.",
keywords = "Clinical trial simulation, DATATOP, Disease progress model, ELLDOPA, Parkinson's disease, Protective treatment",
author = "Chan, {Phylinda L S} and John Nutt and Holford, {Nicholas H G}",
year = "2007",
month = "4",
doi = "10.1007/s11095-006-9202-3",
language = "English (US)",
volume = "24",
pages = "791--802",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Levodopa slows progression of Parkinson's disease. External validation by clinical trial simulation

AU - Chan, Phylinda L S

AU - Nutt, John

AU - Holford, Nicholas H G

PY - 2007/4

Y1 - 2007/4

N2 - Purpose. To externally validate the model predictions of a DATATOP cohort analysis through application of clinical trial simulation with the study design of the ELLDOPA trial. Methods. The stochastic pharmacokinetic-pharmacodynamic and disease progress model was developed from the large DATATOP cohort of patients followed for 8 years. ELLDOPA was designed to detect a difference between placebo and levodopa treated arms in the total Unified Parkinson's Disease Rating Scale (UPDRS) taken at baseline and following 2 weeks levodopa washout after 40 weeks of treatment. The total UPDRS response was simulated with different assumptions on levodopa effect (symptomatic with/without disease modifying capability) and washout speed of symptomatic effect. Results. The observed results of ELLDOPA were similar to the model predictions assuming levodopa slows disease progression and has a slow washout of symptomatic effect. Conclusions. This simulation work confirmed the conclusion of the DATATOP analysis finding that levodopa slows disease progression. The simulation results also showed that a dose-related increased rate of progression in Parkinson's disease, obscured by symptomatic benefit, is very unlikely. Finally, the simulation results also shown that 2 weeks washout period was not adequate to completely eliminate the symptomatic benefits of levodopa.

AB - Purpose. To externally validate the model predictions of a DATATOP cohort analysis through application of clinical trial simulation with the study design of the ELLDOPA trial. Methods. The stochastic pharmacokinetic-pharmacodynamic and disease progress model was developed from the large DATATOP cohort of patients followed for 8 years. ELLDOPA was designed to detect a difference between placebo and levodopa treated arms in the total Unified Parkinson's Disease Rating Scale (UPDRS) taken at baseline and following 2 weeks levodopa washout after 40 weeks of treatment. The total UPDRS response was simulated with different assumptions on levodopa effect (symptomatic with/without disease modifying capability) and washout speed of symptomatic effect. Results. The observed results of ELLDOPA were similar to the model predictions assuming levodopa slows disease progression and has a slow washout of symptomatic effect. Conclusions. This simulation work confirmed the conclusion of the DATATOP analysis finding that levodopa slows disease progression. The simulation results also showed that a dose-related increased rate of progression in Parkinson's disease, obscured by symptomatic benefit, is very unlikely. Finally, the simulation results also shown that 2 weeks washout period was not adequate to completely eliminate the symptomatic benefits of levodopa.

KW - Clinical trial simulation

KW - DATATOP

KW - Disease progress model

KW - ELLDOPA

KW - Parkinson's disease

KW - Protective treatment

UR - http://www.scopus.com/inward/record.url?scp=33947105151&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947105151&partnerID=8YFLogxK

U2 - 10.1007/s11095-006-9202-3

DO - 10.1007/s11095-006-9202-3

M3 - Article

C2 - 17308968

AN - SCOPUS:33947105151

VL - 24

SP - 791

EP - 802

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 4

ER -